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Abstract  
Firstly described by Robert Douglas Sweet in 1964, febrile neutrophilic dermatosis is a disabling, not only 
cutaneous disorder, clinically characterised by fever and painful erythematous nodules, with a typical background 
of neutrophilia. Sweet’s syndrome (SS) is a chronic inflammatory reactive disorder of unknown cause and 
incompletely established pathogenesis, although an interplay between genetic and environmental factors, 
including infections, is likely to occur. A significant part of cases has been demonstrated to be linked with 
malignancies, especially in the hematologic setting. Because of the underlying disease and related therapeutic 
measures, SS may present atypical clinical course, whereas the response to treatment is strictly dependent on 
the concurrent hematologic disease. Herein we describe a case of a lady who had a refractory form of SS, 
resulted in a paraneoplastic cutaneous disease, and AML. Surprisingly, clinical remission of SS followed cytotoxic 
chemotherapy while hematologic disorder obtained a further complete response. 
 
 
 
 
 
 
 
 
Introduction 
 
Sweet syndrome (SS), or acute febrile 
neutrophilic dermatosis [1], is a rare inflammatory 
condition characterised by painful cutaneous nodules 
and neutrophilic infiltrate in the dermis, in the absence 
of vasculitis. SS is a potentially disabling disease, 
significantly associated with malignancies (15-20% of 
cases). Among these, hematologic neoplasms, 
particularly acute myeloid leukaemia (AML) and 
myelodysplastic syndromes are the most commonly 
reported [2][3]. 
Herein we describe a case of a lady who had 
a refractory form of SS, resulted in a paraneoplastic 
cutaneous disease, and AML. Surprisingly, clinical 
remission of SS followed cytotoxic chemotherapy 
while hematologic disorder obtained a further 
complete response. 
 
 
Case report 
 
A 72 – year - old woman was admitted in 
2015 because of several erythematous lesions on the 
dorsal surfaces of both the lower extremities. They 
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were initially suspicious for pyoderma gangrenosum, 
so she was treated with oral prednisone and 
gentamicin ointment topically, with partial response. 
Six months later similar lesions recurred at the same 
anatomical sites, now presenting as erythematous, 
painful, popular and nodular skin lesions, showing 
pustule sporadically on the top (Fig 1a, 1b). The 
patient was afebrile, with slight leucocytosis, 
Erythrocyte Sedimentation Rate >20mm/hour and 
positive CRP protein. Anamnestic personal data were 
positive for COPD and Charcot Marie-Tooth disease, 
whereas a family history of leukaemia was referred. A 
skin biopsy was performed, showing a dense 
neutrophilic dermal infiltrate without vascular aspects 
of leukocytoclasia; the morphological findings covered 
the highest number of criteria for the diagnosis of 
acute neutrophilic dermatosis (Figs 1c, 1d, 1e 1f). 
 
Figure 1: Nodular skin lesions localised at legs (a) and thighs (b). 
Incisional biopsy revealed normal epidermis and dense 
inflammatory infiltrate in the dermis (c), mainly composed of 
lymphocytes and histiocytes (d) [Haematoxylin and eosin stain, 
x40]. The infiltration extended to the subcutaneous adipose tissue 
(e), showing a pale neutrophilic background (f) [Haematoxylin and 
eosin stain, x100] 
 
In the meanwhile, she was commenced on 
oral prednisone (0.75 mg/kg for five days and gradual 
tapering of the dosage) achieving only temporary 
relief of signs and symptoms with recurrence of 
manifestations. A hematologic consultation was also 
obtained together with blood exams: anemia [RBC at 
2,600,000 mmc (n.r. 4,200,000-5,400,000), HGB at 89 
g/L (n.r. 120 - 160), thrombocytopenia [PLT at 42,000 
(n.r. 130,000-260,000)] and the presence of blasts, 
prompted a bone marrow examination that revealed 
43% of blasts and multilineage dysplasia. A diagnosis 
of acute myelogenous leukaemia was made, 
cytogenetics also supporting the diagnosis through 
the evidence of deletion of 5q [- 5/del (5q)]. Gene 
mutations in fms - related tyrosine kinase - 3 (FLT3) 
gene [FLT3 - internal tandem duplication] were also 
found. 
Supportive care for cytopenia was 
established, using erythropoietin, red blood cells 
transfusions with iron chelation therapy and platelet 
transfusions. 
Treatment with cytarabine (200 mg daily for 
seven days) plus epirubicin (75 mg daily for three 
days) was started. Methylprednisolone 40 mg/day 
intravenously was also prescribed and tapered over 
two weeks. Supportive antibiotics, including 
vancomycin and meropenem, were added during the 
hospital stay. 
Cytostatic therapy was well tolerated without 
serious adverse effect, except for neutropenia, which 
required occasional dose reduction. After the first 
cycle, a complete remission of cutaneous 
manifestations of SS happened, with the improvement 
of blood values and marrow histology after three 
cycles. The patient is also undergoing the fourth cycle 
of treatment with further hematologic improvement 
and no new skin lesions. 
 
 
Discussion 
 
Sweet’s syndrome, or acute febrile 
neutrophilic dermatosis, is an uncommon, severe 
cutaneous condition, characterized by the abrupt 
development of painful, tender, erythematous 
plaques, fever greater than 38°C, and a nodular 
perivascular neutrophilic dermal infiltrate without 
evidence of vasculitis on histologic examination [1][3]. 
Although frequently idiopathic, similarly to 
other diseases in this ‘reactive’ setting4, SS may 
develop in association with other systemic disorders 
or in the presence of identifiable triggers, including 
underlying autoimmune disorders, pregnancy, 
antecedent vaccination, drug assumption, 
inflammatory bowel disease, or infections [5][6].  
The so-called ‘malignancy-associated Sweet’s 
syndrome’ accounts for 15-20% of total cases of SS, 
and occurs in the association, or as a consequence, 
with both haematological and visceral malignancies 
[2]. 
In this setting, AML constitutes the most 
reported in clinical practice [2][7]. 
In fact, SS could present as a paraneoplastic 
 Tchernev et al. Sweet’s Syndrome (SS) in Course of Acute Myeloid Leukaemia (AML) 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         3 
 
cutaneous manifestation or as a drug-induced SS due 
to medications commonly used in the treatment of 
AML [8]. 
The aberrant production of both pro-
inflammatory cytokines (IL - 6, TNF - alpha) and 
signalling molecules, that has been demonstrated in 
AML and SS, may affect neutrophil function, finally 
contributing to the dermal clumping of the mature 
neutrophils [7][9]. 
According to with literature, SS is relatively 
rare in general population whereas it occurs in about 
1% of patients with AML [6]. 
 It also occurs more commonly in females and 
at various stages, including pre-diagnosis, at 
diagnosis, at the commencement of therapy, during 
remission and with relapse [7][10], thus representing 
such as a “marker” of AML disease activity. 
 Dealing with the data by Kazmi et al., [7], 
about 33% of patients receive the diagnoses of SS 
and AML at the same time, whereas another third of 
them during treatment of relapsed disease, and 29% 
during primary induction of chemotherapy. About 
diagnostic criteria, anaemia and thrombocytopenia are 
present in almost all patients, with fever being 
reported only in two-thirds of cases, as well as 
neutrophilia and elevated erythrocyte sedimentation 
rate. Clinical manifestations were classically 
multifocal, diffuse and asymmetrical. Cytogenetic 
characterisation revealed mainly changes in 
chromosome 5 (38% of cases) [7].  
Glucocorticoids, either topical or systemic, 
together with antibiotics and wound care, represent 
the mainstays of SS therapy [11].  
Although they showed to be highly 
efficacious, some recalcitrant cases may significantly 
benefit from the treatment of the underlying AML, and 
of infections, through the restoration of normal 
granulocyte function. 
Our case was consistent with the above-
mentioned characteristics. Initial cutaneous 
manifestations were probably underestimated, 
because of not typical features of the lesions, and the 
diagnosis of leukaemia might be obscured by steroid 
administration. 
Anyway, although rare and sometimes difficult 
to be discovered because of the wide spectrum of 
differential diagnoses, when SS is established, the 
physician should keep a high index of suspicion to 
search underlying malignancies. In the same way, 
sign and symptoms of SS have to be searched for the 
diagnosis of AML. 
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